Interference 102,728 In addition, we find that in para. 9 of his declaration, Dr. Falkinham cites to column 2, line 68, and column 3, line 25.27 Thus, we agree with Brake that Dr. Falkinham is discussing the Brake patent which is based on Brake’s continuation-in- part, Application 06/522,909 (Brake 2), filed August 12, 1983. Accordingly, we find that Dr. Falkinham’s conclusion that “[o]ne skilled in the art would have determined from the Brake specification that the n=0 construct was not desirable,” is inconsistent with the evidence of record. That is, the Brake specification from which Dr. Falkinham draws his conclusion that the “n=0” construct is not desirable is the very specification which contains the claim which is the subject matter of this interference. Claim 1 of the Brake patent (Brake 2) is identical to Count 1 of this interference. Singh further argues that modifying genetic constructs was unpredictable at the time the Brake 1 application was filed. Paper No. 30, p. 14. Singh relies on paragraph 10 of Dr. Falkinham’s declaration for support. Dr. Falkinham states: Brake attested to this unpredictability at page 14 of the 06/522,909 application, where “Surprisingly, a deletion occurred where the codon for the 3rd and 5th amino acids for EGF, asp and ser, were deleted with the remainder of the EGF being retained” [emphasis added] [Falkinham declaration, pp. 3-4, para. 10]. We find this argument unconvincing. It is not clear to us, and Dr. Falkinham does not explain, how this section of the Brake 2 specification, which describes the addition of synthetic linkers to a DNA 27 Brake points out that Dr. Falkinham has misunderstood the teachings at column 3, line 25, of the Brake patent. Brake Reply, Paper No. 44, p. 13. The referenced section of the patent provides that r’ is “2 to 4, preferably 2 or 4" when “n is 0.” Id. We find that unreliable testimony, such as this, undermines Dr. Falkinham’s credibility as an expert witness. 36Page: Previous 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 NextLast modified: November 3, 2007